Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03400943 · ClinicalTrials.gov registry record · Phase 3
Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)
A Phase 3 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 93
- Enrollment target
NCT03400943 is a Phase 3 study that was terminated before completion, run by Bayer. The registered enrollment target is 93 participants.
The verdict
NCT03400943, a Phase 3 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 93 participants
- Enrollment target
Study Summary
The primary objective of this study was to show superiority in the treatment of HMB of vilaprisan in subjects with uterine fibroids compared to placebo. The secondary objectives of this study were to additionally evaluate the efficacy and safety of vilaprisan in subjects with uterine fibroids.
Interventions
- DRUG Placebo
- DRUG Vilaprisan (BAY1002670)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2018-01-17 |
| Est. Completion | 2022-04-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03400943
The ClinicalTrials.gov registry entry for NCT03400943 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03400943 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03400943 about?
NCT03400943 is a clinical study titled "Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)". The primary objective of this study was to show superiority in the treatment of HMB of vilaprisan in subjects with uterine fibroids compared to placebo. The secondary objectives of this study were to additionally evaluate the efficacy and safety of vilaprisan in subjects with uterine fibroids.
What is the current status of trial NCT03400943?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 93 participants. The study started on 2018-01-17. Estimated completion is 2022-04-06.
What interventions are being tested in trial NCT03400943?
The interventions under investigation include: Placebo (DRUG), Vilaprisan (BAY1002670) (DRUG).
Who is sponsoring clinical trial NCT03400943?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.